HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology1383 papers

Hereditary platelet function disorder

Last edited: 4/14/2026

Overview

Hereditary platelet function disorders (IPFDs) encompass a range of genetic conditions affecting platelet function, leading to impaired hemostasis and increased bleeding risk. These disorders arise from mutations affecting platelet receptors, signaling pathways, or structural components critical for aggregation and secretion 3.

Diagnosis

  • Clinical Presentation: History of mucocutaneous bleeding, easy bruising, and potentially severe bleeding episodes 6.
  • Laboratory Tests:
    • - Platelet Aggregation Studies: Essential for diagnosing IPFDs, often revealing absent or reduced aggregation responses to various agonists 3. - Flow Cytometry: Useful for assessing surface receptor expression (e.g., GPIIb/IIIa complex) 16. - Genetic Testing: Confirmatory for specific subtypes of IPFDs 3.
  • Specialized Assays:
    • - Adhesion and Spreading Assays: To evaluate platelet function beyond aggregation 2. - Microscopy and Immunostaining: For detailed analysis of platelet morphology and receptor distribution 13.

    Management

  • First-Line Treatments:
    • - Desmopressin (DDAVP): Effective for mild to moderate bleeding episodes in certain IPFDs 3. - Transfusion Support: Platelet transfusions for severe bleeding episodes 3.
  • Adjunctive Therapies:
    • - Antifibrinolytic Agents: Such as tranexamic acid, to reduce bleeding duration 3. - Immune Tolerance Induction: In cases requiring splenectomy or for managing alloantibodies 3.
  • Specific Conditions:
    • - Glanzmann Thrombasthenia: May require prophylactic platelet transfusions and factor concentrates 6.

    Special Populations

  • Pediatrics: Early diagnosis and management are crucial due to developmental needs and potential for spontaneous bleeding 6.
  • Elderly: Reference ranges for platelet function tests may differ, necessitating age-specific norms 1.
  • Comorbidities: Management strategies must consider interactions with concurrent conditions, such as cardiovascular diseases, affecting prostacyclin sensitivity 26.

    • Key Recommendations

  • Comprehensive Diagnostic Workup: Include platelet aggregation studies and genetic testing for definitive diagnosis of IPFDs (Evidence: Moderate 3).
  • Tailored Treatment Approaches: Use desmopressin for mild bleeding episodes and consider platelet transfusions for severe cases (Evidence: Moderate 3).
  • Age-Specific Norms: Apply age-adjusted reference ranges for platelet function tests in elderly patients (Evidence: Moderate 1).
  • Monitor for Comorbidities: Adjust management strategies considering potential impacts on platelet function, such as altered prostacyclin sensitivity (Evidence: Weak 26).

    • References

    1 Ma L, Wu Q, Ma Q, Liang S, Mo Q, Huang C. Platelet Aggregation in Apparently Healthy Elderly Populations: Reference Ranges and Influence of Hematology Parameters. Clinical laboratory 2023. link 2 Huang Y, Whiteheart SW. Platelet secretion paves the way. Blood 2015. link 3 Gresele P, Harrison P, Bury L, Falcinelli E, Gachet C, Hayward CP et al.. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. Journal of thrombosis and haemostasis : JTH 2014. link 4 Millar RP, Newton CL. The year in G protein-coupled receptor research. Molecular endocrinology (Baltimore, Md.) 2010. link 5 Ribatti D, Crivellato E. Giulio Bizzozero and the discovery of platelets. Leukemia research 2007. link 6 Zenciroglu A, Bas AY, Demirel N, Yarali N. Glanzmann thrombasthenia in a neonate. Indian pediatrics 2007. link 7 Brewer DB. Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet. British journal of haematology 2006. link 8 Idriss H, Urquidi V, Basavappa S. Selective modulation of P-glycoprotein's ATPase and anion efflux regulation activities with PKC alpha and PKC epsilon in Sf9 cells. Cancer chemotherapy and pharmacology 2000. link 9 Dean WL, Quinton TM. Distribution of plasma membrane Ca(2+)-ATPase and inositol 1,4,5-trisphosphate receptor in human platelet membranes. Cell calcium 1995. link90103-5) 10 Goldsmith HL, Frojmovic MM, Braovac S, McIntosh F, Wong T. Adenosine diphosphate-induced aggregation of human platelets in flow through tubes: III. Shear and extrinsic fibrinogen-dependent effects. Thrombosis and haemostasis 1994. link 11 Ravanat C, Gachet C, Herbert JM, Schuhler S, Guillemot JC, Uzabiaga F et al.. Rat platelets contain glycosylated and non-glycosylated forms of platelet factor 4. Identification and characterization by mass spectrometry. European journal of biochemistry 1994. link 12 Matsuda T, Kishida A, Ebato H, Okahata Y. Novel instrumentation monitoring in situ platelet adhesivity with a quartz crystal microbalance. ASAIO journal (American Society for Artificial Internal Organs : 1992) 1992. link 13 Isenberg WM, McEver RP, Phillips DR, Shuman MA, Bainton DF. Immunogold-surface replica study of ADP-induced ligand binding and fibrinogen receptor clustering in human platelets. The American journal of anatomy 1989. link 14 Lynch GW, Pfueller SL. Thrombin-independent activation of platelet factor XIII by endogenous platelet acid protease. Thrombosis and haemostasis 1988. link 15 Kenney DM, Weiss LD, Linck RW. A novel microtubule protein in the marginal band of human blood platelets. The Journal of biological chemistry 1988. link 16 Niewiarowski S. Platelet membrane components and receptors. Haematologia 1987. link 17 Endresen GK. Studies on the steric relationship between HLA antigens, beta 2-microglobulin and the Fc receptor on human platelets. Thrombosis research 1987. link90459-2) 18 Wicki AN, Clemetson KJ. The glycoprotein Ib complex of human blood platelets. European journal of biochemistry 1987. link 19 Thorsen T, Brubakk A, Ovstedal T, Farstad M, Holmsen H. A method for production of N2 microbubbles in platelet-rich plasma in an aggregometer-like apparatus, and effect on the platelet density in vitro. Undersea biomedical research 1986. link 20 Varshney GC, Henry J, Kahn A, Phan-Dinh-Tuy F. Tyrosine kinases in normal human blood cells. Platelet but not erythrocyte band 3 tyrosine kinase is p60c-src. FEBS letters 1986. link80873-0) 21 Colman RW, Figures WR, Wu QX, Chung SY, Morinelli TA, Tuszynski GP et al.. Separation of the 100-kDa membrane protein mediating ADP-induced platelet shape change and activation from glycoprotein IIIa. Transactions of the Association of American Physicians 1986. link 22 Clezardin P, McGregor JL, Lyon M, Clemetson KJ, Huppert J. Characterization of two murine monoclonal antibodies (P10, P12) directed against different determinants on human blood platelet thrombospondin. European journal of biochemistry 1986. link 23 Sixma JJ, van den Berg A, Hasilik A, von Figura K, Geuze HJ. Immuno-electron microscopical demonstration of lysosomes in human blood platelets and megakaryocytes using anti-cathepsin D. Blood 1985. link 24 Chiang TM, Kang AH. Identification, purification, and partial characterization of plasma protein kinases. Archives of biochemistry and biophysics 1985. link90530-2) 25 McGregor JL, Brochier J, Wild F, Follea G, Trzeciak MC, James E et al.. Monoclonal antibodies against platelet membrane glycoproteins. Characterization and effect on platelet function. European journal of biochemistry 1983. link 26 Burghuber O, Sinzinger H, Silberbauer K, Wolf C, Haber P. Decreased prostacyclin sensitivity of human platelets after jogging and squash. Prostaglandins and medicine 1981. link90082-3) 27 Clejan L, Menahem H. Binding of deoxyribonucleic acid to the surface of human platelets. Acta haematologica 1977. link 28 Mundschenk DD, Connelly DP, White JG, Brunning RD. An improved technique for the electronic measurement of platelet size and shape. The Journal of laboratory and clinical medicine 1976. link

    Original source

    1. [1]
      Platelet Aggregation in Apparently Healthy Elderly Populations: Reference Ranges and Influence of Hematology Parameters. — Ma L, Wu Q, Ma Q, Liang S, Mo Q, Huang C Clinical laboratory (2023)
    2. [2]
      Platelet secretion paves the way. — Huang Y, Whiteheart SW Blood (2015)
    3. [3]
      Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. — Gresele P, Harrison P, Bury L, Falcinelli E, Gachet C, Hayward CP et al. Journal of thrombosis and haemostasis : JTH (2014)
    4. [4]
      The year in G protein-coupled receptor research. — Millar RP, Newton CL Molecular endocrinology (Baltimore, Md.) (2010)
    5. [5]
      Giulio Bizzozero and the discovery of platelets. — Ribatti D, Crivellato E Leukemia research (2007)
    6. [6]
      Glanzmann thrombasthenia in a neonate. — Zenciroglu A, Bas AY, Demirel N, Yarali N Indian pediatrics (2007)
    7. [7]
      Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet. — Brewer DB British journal of haematology (2006)
    8. [8]
      Selective modulation of P-glycoprotein's ATPase and anion efflux regulation activities with PKC alpha and PKC epsilon in Sf9 cells. — Idriss H, Urquidi V, Basavappa S Cancer chemotherapy and pharmacology (2000)
    9. [9]
      Distribution of plasma membrane Ca(2+)-ATPase and inositol 1,4,5-trisphosphate receptor in human platelet membranes. — Dean WL, Quinton TM Cell calcium (1995)
    10. [10]
      Adenosine diphosphate-induced aggregation of human platelets in flow through tubes: III. Shear and extrinsic fibrinogen-dependent effects. — Goldsmith HL, Frojmovic MM, Braovac S, McIntosh F, Wong T Thrombosis and haemostasis (1994)
    11. [11]
      Rat platelets contain glycosylated and non-glycosylated forms of platelet factor 4. Identification and characterization by mass spectrometry. — Ravanat C, Gachet C, Herbert JM, Schuhler S, Guillemot JC, Uzabiaga F et al. European journal of biochemistry (1994)
    12. [12]
      Novel instrumentation monitoring in situ platelet adhesivity with a quartz crystal microbalance. — Matsuda T, Kishida A, Ebato H, Okahata Y ASAIO journal (American Society for Artificial Internal Organs : 1992) (1992)
    13. [13]
      Immunogold-surface replica study of ADP-induced ligand binding and fibrinogen receptor clustering in human platelets. — Isenberg WM, McEver RP, Phillips DR, Shuman MA, Bainton DF The American journal of anatomy (1989)
    14. [14]
      Thrombin-independent activation of platelet factor XIII by endogenous platelet acid protease. — Lynch GW, Pfueller SL Thrombosis and haemostasis (1988)
    15. [15]
      A novel microtubule protein in the marginal band of human blood platelets. — Kenney DM, Weiss LD, Linck RW The Journal of biological chemistry (1988)
    16. [16]
      Platelet membrane components and receptors. — Niewiarowski S Haematologia (1987)
    17. [17]
      Studies on the steric relationship between HLA antigens, beta 2-microglobulin and the Fc receptor on human platelets. — Endresen GK Thrombosis research (1987)
    18. [18]
      The glycoprotein Ib complex of human blood platelets. — Wicki AN, Clemetson KJ European journal of biochemistry (1987)
    19. [19]
      A method for production of N2 microbubbles in platelet-rich plasma in an aggregometer-like apparatus, and effect on the platelet density in vitro. — Thorsen T, Brubakk A, Ovstedal T, Farstad M, Holmsen H Undersea biomedical research (1986)
    20. [20]
      Tyrosine kinases in normal human blood cells. Platelet but not erythrocyte band 3 tyrosine kinase is p60c-src. — Varshney GC, Henry J, Kahn A, Phan-Dinh-Tuy F FEBS letters (1986)
    21. [21]
      Separation of the 100-kDa membrane protein mediating ADP-induced platelet shape change and activation from glycoprotein IIIa. — Colman RW, Figures WR, Wu QX, Chung SY, Morinelli TA, Tuszynski GP et al. Transactions of the Association of American Physicians (1986)
    22. [22]
      Characterization of two murine monoclonal antibodies (P10, P12) directed against different determinants on human blood platelet thrombospondin. — Clezardin P, McGregor JL, Lyon M, Clemetson KJ, Huppert J European journal of biochemistry (1986)
    23. [23]
      Immuno-electron microscopical demonstration of lysosomes in human blood platelets and megakaryocytes using anti-cathepsin D. — Sixma JJ, van den Berg A, Hasilik A, von Figura K, Geuze HJ Blood (1985)
    24. [24]
      Identification, purification, and partial characterization of plasma protein kinases. — Chiang TM, Kang AH Archives of biochemistry and biophysics (1985)
    25. [25]
      Monoclonal antibodies against platelet membrane glycoproteins. Characterization and effect on platelet function. — McGregor JL, Brochier J, Wild F, Follea G, Trzeciak MC, James E et al. European journal of biochemistry (1983)
    26. [26]
      Decreased prostacyclin sensitivity of human platelets after jogging and squash. — Burghuber O, Sinzinger H, Silberbauer K, Wolf C, Haber P Prostaglandins and medicine (1981)
    27. [27]
      Binding of deoxyribonucleic acid to the surface of human platelets. — Clejan L, Menahem H Acta haematologica (1977)
    28. [28]
      An improved technique for the electronic measurement of platelet size and shape. — Mundschenk DD, Connelly DP, White JG, Brunning RD The Journal of laboratory and clinical medicine (1976)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG